432 related articles for article (PubMed ID: 18613260)
1. The state of dietary supplement adverse event reporting in the United States.
Gardiner P; Sarma DN; Low Dog T; Barrett ML; Chavez ML; Ko R; Mahady GB; Marles RJ; Pellicore LS; Giancaspro GI
Pharmacoepidemiol Drug Saf; 2008 Oct; 17(10):962-70. PubMed ID: 18613260
[TBL] [Abstract][Full Text] [Related]
2. United States pharmacopeia safety evaluation of spirulina.
Marles RJ; Barrett ML; Barnes J; Chavez ML; Gardiner P; Ko R; Mahady GB; Low Dog T; Sarma ND; Giancaspro GI; Sharaf M; Griffiths J
Crit Rev Food Sci Nutr; 2011 Aug; 51(7):593-604. PubMed ID: 21793723
[TBL] [Abstract][Full Text] [Related]
3. FDA regulation of dietary supplements and requirements regarding adverse event reporting.
Frankos VH; Street DA; O'Neill RK
Clin Pharmacol Ther; 2010 Feb; 87(2):239-44. PubMed ID: 20032973
[TBL] [Abstract][Full Text] [Related]
4. Adverse drug event surveillance and drug withdrawals in the United States, 1969-2002: the importance of reporting suspected reactions.
Wysowski DK; Swartz L
Arch Intern Med; 2005 Jun; 165(12):1363-9. PubMed ID: 15983284
[TBL] [Abstract][Full Text] [Related]
5. Dietary supplement adverse event reports: review and analysis.
Talati AR; Gurnani AK
Food Drug Law J; 2009; 64(3):503-13. PubMed ID: 19999641
[TBL] [Abstract][Full Text] [Related]
6. Role of US poison centers in adverse drug reactions monitoring.
Chyka PA
Vet Hum Toxicol; 1999 Dec; 41(6):400-2. PubMed ID: 10592954
[TBL] [Abstract][Full Text] [Related]
7. Pediatric drug surveillance and the Food and Drug Administration's adverse event reporting system: an overview of reports, 2003-2007.
Johann-Liang R; Wyeth J; Chen M; Cope JU
Pharmacoepidemiol Drug Saf; 2009 Jan; 18(1):24-7. PubMed ID: 19009550
[TBL] [Abstract][Full Text] [Related]
8. Physicians' understanding of the regulation of dietary supplements.
Ashar BH; Rice TN; Sisson SD
Arch Intern Med; 2007 May; 167(9):966-9. PubMed ID: 17502539
[TBL] [Abstract][Full Text] [Related]
9. An evaluation of a data mining signal for amyotrophic lateral sclerosis and statins detected in FDA's spontaneous adverse event reporting system.
Colman E; Szarfman A; Wyeth J; Mosholder A; Jillapalli D; Levine J; Avigan M
Pharmacoepidemiol Drug Saf; 2008 Nov; 17(11):1068-76. PubMed ID: 18821724
[TBL] [Abstract][Full Text] [Related]
10. Can claims, misleading information, and manufacturing issues regarding dietary supplements be improved in the United States?
Gibson JE; Taylor DA
J Pharmacol Exp Ther; 2005 Sep; 314(3):939-44. PubMed ID: 15833895
[TBL] [Abstract][Full Text] [Related]
11. The role of databases in drug postmarketing surveillance.
Rodriguez EM; Staffa JA; Graham DJ
Pharmacoepidemiol Drug Saf; 2001; 10(5):407-10. PubMed ID: 11802586
[TBL] [Abstract][Full Text] [Related]
12. Estimating the extent of reporting to FDA: a case study of statin-associated rhabdomyolysis.
McAdams M; Staffa J; Dal Pan G
Pharmacoepidemiol Drug Saf; 2008 Mar; 17(3):229-39. PubMed ID: 18175291
[TBL] [Abstract][Full Text] [Related]
13. Antipsychotics, glycemic disorders, and life-threatening diabetic events: a Bayesian data-mining analysis of the FDA adverse event reporting system (1968-2004).
DuMouchel W; Fram D; Yang X; Mahmoud RA; Grogg AL; Engelhart L; Ramaswamy K
Ann Clin Psychiatry; 2008; 20(1):21-31. PubMed ID: 18297583
[TBL] [Abstract][Full Text] [Related]
14. Topical bovine thrombin: a 21-year review of topical bovine thrombin spontaneous case safety reports submitted to FDA's Adverse Event Reporting System.
Clark JA; Humphries JE; Crean S; Reynolds MW
Pharmacoepidemiol Drug Saf; 2010 Feb; 19(2):107-14. PubMed ID: 20014051
[TBL] [Abstract][Full Text] [Related]
15. United States Pharmacopeia review of the black cohosh case reports of hepatotoxicity.
Mahady GB; Low Dog T; Barrett ML; Chavez ML; Gardiner P; Ko R; Marles RJ; Pellicore LS; Giancaspro GI; Sarma DN
Menopause; 2008; 15(4 Pt 1):628-38. PubMed ID: 18340277
[TBL] [Abstract][Full Text] [Related]
16. Serious adverse events in Norplant users reported to the Food and Drug Administration's MedWatch Spontaneous Reporting System.
Wysowski DK; Green L
Obstet Gynecol; 1995 Apr; 85(4):538-42. PubMed ID: 7898829
[TBL] [Abstract][Full Text] [Related]
17. Challenges in collecting, accessing and evaluating post market surveillance AERS in patients receiving dietary supplements.
Kingston R
Thromb Res; 2005; 117(1-2):137-44; discussion 145-51. PubMed ID: 16139875
[No Abstract] [Full Text] [Related]
18. Improving the quality of adverse drug reaction reporting by 4th-year medical students.
Rosebraugh CJ; Tsong Y; Zhou F; Chen M; Mackey AC; Flowers C; Toyer D; Flockhart DA; Honig PK
Pharmacoepidemiol Drug Saf; 2003 Mar; 12(2):97-101. PubMed ID: 12642973
[TBL] [Abstract][Full Text] [Related]
19. Dietary supplements: physician knowledge and adverse event reporting.
Cellini M; Attipoe S; Seales P; Gray R; Ward A; Stephens M; Deuster PA
Med Sci Sports Exerc; 2013 Jan; 45(1):23-8. PubMed ID: 22811037
[TBL] [Abstract][Full Text] [Related]
20. Time-to-signal comparison for drug safety data-mining algorithms vs. traditional signaling criteria.
Hochberg AM; Hauben M
Clin Pharmacol Ther; 2009 Jun; 85(6):600-6. PubMed ID: 19322165
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
